Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | PLK4 | O00444 | 2/20 | 0.33 |
| ▸ | AURKA | O14965 | 2/20 | 0.33 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.33 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.33 |
| ▸ | CDK1 | P06493 | 2/20 | 0.33 |
| ▸ | PIM1 | P11309 | 2/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.33 |
| ▸ | PRKACA | P17612 | 2/20 | 0.33 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.33 |
| ▸ | CDK2 | P24941 | 2/20 | 0.33 |
| ▸ | MARK3 | P27448 | 2/20 | 0.33 |
| ▸ | FLT4 | P35916 | 2/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.33 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.33 |
| ▸ | GSK3A | P49840 | 2/20 | 0.33 |
| ▸ | GSK3B | P49841 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9956920 | 0.86 | EGLN1 (0.33) | IDO1KDM4ENPC1MAPTRAB9A | |
| SCHEMBL9957616 | 0.81 | MAPT (0.38) | PTPN2KDM4EMAPT | |
| SCHEMBL280594 | 0.74 | PLG (0.39) | DGAT1DAPK3CDK1PIM1PRKACA | |
| SCHEMBL4777702 | 0.74 | DGAT1 (0.39) | DGAT1DAPK3CDK1PIM1PRKACA | |
| SCHEMBL31028460 | 0.74 | DYRK1A (0.38) | PLK4AURKADAPK3CHEK2CDK1 | |
| SCHEMBL24898414 | 0.74 | BCKDK (0.40) | PLK4AURKADAPK3CHEK2CDK1 | |
| SCHEMBL20529391 | 0.71 | KDM4E (0.31) | KDM4EMAPT | |
| SCHEMBL12713955 | 0.69 | LRRK2 (0.50) | DYRK1ANPC1MAPTRAB9A | |
| SCHEMBL9957882 | 0.69 | IDO1 (0.33) | DGAT1IDO1KDM4ENPC1MAPT | |
| SCHEMBL23088340 | 0.68 | ALDH1A1 (0.40) | KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655370-B1 | COMPOSITIONS AND METHODS FOR MODULATING FXR | NOVARTIS AG (CH) | 2017-08-02 | — | — | EP | disclosed |
| EP-2655370-B1 | COMPOSITIONS AND METHODS FOR MODULATING FXR | NOVARTIS AG (CH) | 2017-08-02 | — | — | EP | disclosed |
| US-20150366856-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NOVARTIS AG (CH) | 2015-12-24 | — | — | US | disclosed |
| US-20150366856-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NOVARTIS AG (CH) | 2015-12-24 | — | — | US | disclosed |
| US-20150366856-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NOVARTIS AG (CH) | 2015-12-24 | — | — | US | disclosed |
| US-9150568-B2 | Compositions and methods for modulating FXR | NOVARTIS AG (CH) | 2015-10-06 | — | — | US | disclosed |
| US-9150568-B2 | Compositions and methods for modulating FXR | NOVARTIS AG (CH) | 2015-10-06 | — | — | US | disclosed |
| US-9150568-B2 | Compositions and methods for modulating FXR | NOVARTIS AG (CH) | 2015-10-06 | — | — | US | disclosed |
| US-20130331349-A1 | COMPOSITIONS AND METHODS FOR MODULATING FXR | IRM LLC (BM) | 2013-12-12 | — | — | US | disclosed |
| EP-2655370-A1 | COMPOSITIONS AND METHODS FOR MODULATING FXR | IRM LLC (BM) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012087519-A1 | COMPOSITIONS AND METHODS FOR MODULATING FXR | IRM LLC (BM) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012087519-A1 | COMPOSITIONS AND METHODS FOR MODULATING FXR | IRM LLC (BM) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150366856-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, SLC10A1, FXR1 | DGAT1 571/4885PLK4 4327/4885AURKA 2891/4885 |
| US-20130331349-A1 | COMPOSITIONS AND METHODS FOR MODULATING FXR | NR1H4, SLC10A1, FXR1 | DGAT1 598/4885PLK4 4471/4885AURKA 3076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.